Business Context and Reporting Period
Company: Mustang Bio, Inc. (MBIO)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: Mustang Bio is a clinical-stage biopharmaceutical company focused on CAR T therapies for hematologic malignancies, autoimmune diseases, and solid tumors. The company is a majority-controlled subsidiary of Fortress Biotech, Inc. It has no approved products and has not generated product revenue to date.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9 Months 2025 | 9 Months 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(468) | $(1,410) | $(1,383) | $(14,800) |
| Operating Expenses | $624 | $1,457 | $1,762 | $15,228 |
| Cash and Cash Equivalents (End of Period) | $18,984 | $3,900 | $18,984 | $3,900 |
| Accumulated Deficit | $(398,106) | $(395,771) | $(398,106) | $(395,771) |
| Stockholders' Equity | $9,771 | $(8,656) | $9,771 | $(8,656) |
Note: All share and per-share data has been retroactively adjusted for a 1-for-50 reverse stock split effective January 15, 2025.
Material Changes vs. Prior Period
- Significant Reduction in Operating Expenses: Total operating expenses for the nine months ended September 30, 2025, decreased by approximately $13.5 million (88%) compared to the same period in 2024. This was driven by workforce reductions, the termination of the uBriGene transaction, and the closure of the MB-106 clinical trial.
- Research and Development (R&D) Credits: R&D expenses for the nine months ended September 30, 2025, were reported as a net credit of $(1.2) million, compared to $8.2 million in expenses in 2024. This reversal is primarily due to a $1.4 million gain from settling aged payables and a $0.4 million gain from the termination of the Plantation Street Facility lease.
- Asset Impairment: The company recorded a $2.6 million asset impairment charge in the nine months ended September 30, 2024, related to leasehold improvements. No impairment was recorded in the current period.
- Liquidity Improvement: Cash balances increased from $6.8 million at year-end 2024 to $19.0 million at September 30, 2025, primarily due to a February 2025 equity offering ($6.8 million net proceeds) and July 2025 warrant exercises ($7.1 million proceeds).
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has concluded that there is substantial doubt regarding the company's ability to continue as a going concern for the 12 months following the issuance of these financial statements. The company requires substantial additional financing to fund operations and product development.
- Capital Raising Constraints: The company is subject to SEC "baby shelf rules," limiting the amount of securities it can sell under its Form S-3 registration statement to one-third of its public float (currently less than $75 million) in any 12-month period.
- License Termination Risk: In September 2025, the company received notice from Fred Hutch of its intent to terminate the CD20 License (MB-106) for cause due to unpaid patent expenses. The company is negotiating a termination arrangement that may involve potential consideration.
- Unusual Items: The financial results for the current period include non-recurring gains from lease termination and payable settlements, which are not indicative of future operating expenses.
- Outlook: The company plans to explore an investigator-sponsored single-institution study for MB-109 (combination therapy for glioblastoma) potentially initiating in Q2 2026. No revenue is expected in the foreseeable future.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $19.0 million cash balance against current burn rates given the "substantial doubt" going concern disclosure.
- Financing Capacity: Assess the impact of the "baby shelf rules" on the company's ability to raise capital quickly if needed.
- License Status: Monitor the outcome of negotiations with Fred Hutch regarding the CD20 License termination and potential loss of the MB-106 program.
- Expense Sustainability: Confirm that the reported R&D credits (payable settlements and lease gains) are non-recurring and do not mask underlying operational costs.
- Nasdaq Compliance: Verify continued compliance with Nasdaq listing requirements following the recent reverse stock split and equity offering.